Reuters logo
BRIEF-Neurocrine Bio's Ingrezza fails study in pedriatric Tourette's patients
2017年5月23日 / 晚上9点18分 / 4 个月前

BRIEF-Neurocrine Bio's Ingrezza fails study in pedriatric Tourette's patients

May 23 (Reuters) - Neurocrine Biosciences Inc

* Neurocrine announces phase ii results of vmat2 inhibitor ingrezza® for treatment of tourette syndrome

* Neurocrine biosciences inc- study did not meet its primary endpoint

* Neurocrine biosciences inc- there were a total of four discontinuations due to adverse events, two in each of placebo and ingrezza arms in study

* Neurocrine biosciences inc- company is also conducting an open-label, fixed-dose study of ingrezza in up to 180 subjects with tourette syndrome Source text for Eikon: Further company coverage:

我们的标准汤森路透“信任原则”
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below